×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MCRB – seres therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MCRB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/13
02:48 pm
mcrb
Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.
Low
Report
Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.
3/12
07:00 am
mcrb
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Low
Report
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
3/3
10:05 am
mcrb
Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]
Low
Report
Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]
3/2
04:34 pm
mcrb
Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]
Low
Report
Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]
3/2
04:22 pm
mcrb
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]
Low
Report
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]
3/2
04:05 pm
mcrb
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Low
Report
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
2/12
07:00 am
mcrb
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
High
Report
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
2/6
06:36 pm
mcrb
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]
Low
Report
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/12
10:01 am
mcrb
Form 10-K Seres Therapeutics, Inc. For: Dec 31
Low
Report
Form 10-K Seres Therapeutics, Inc. For: Dec 31
3/12
07:06 am
mcrb
Form 8-K Seres Therapeutics, Inc. For: Mar 12
Low
Report
Form 8-K Seres Therapeutics, Inc. For: Mar 12
3/11
06:39 pm
mcrb
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Brady Kelly
Low
Report
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Brady Kelly
3/11
06:31 pm
mcrb
Form 3 Seres Therapeutics, Inc. For: Mar 02 Filed by: Brady Kelly
Low
Report
Form 3 Seres Therapeutics, Inc. For: Mar 02 Filed by: Brady Kelly
3/6
04:37 pm
mcrb
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Kender Richard N
Low
Report
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Kender Richard N
3/6
04:35 pm
mcrb
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Henn Matthew R
Low
Report
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Henn Matthew R
3/6
04:34 pm
mcrb
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Thorell Marella
Low
Report
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: Thorell Marella
3/6
04:32 pm
mcrb
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: DesRosier Thomas
Low
Report
Form 4 Seres Therapeutics, Inc. For: Mar 04 Filed by: DesRosier Thomas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation
17.1%
3/18 Form 424B5 Seres Therapeutics, Inc. 14.2%
8/6 Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.2%
3/23 Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors 9.7%
3/30 Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates 9.5%
4/6 Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer 9.2%
11/5 Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.8%
3/15 Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit 8.8%
6/14 Form 4 Seres Therapeutics, Inc. For: Jun 13 Filed by: Kim Lorence H. 7.5%
4/24 Form 4 Seres Therapeutics, Inc. For: Apr 22 Filed by: Chapman Marcus 6.9%
3/18 Form 424B5 Seres Therapeutics, Inc. 14.2%
8/6 Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.2%
3/23 Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors 9.7%
3/30 Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates 9.5%
4/6 Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer 9.2%
11/5 Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.8%
3/15 Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit 8.8%
6/14 Form 4 Seres Therapeutics, Inc. For: Jun 13 Filed by: Kim Lorence H. 7.5%
4/24 Form 4 Seres Therapeutics, Inc. For: Apr 22 Filed by: Chapman Marcus 6.9%
TOP News Decliners
6/13
Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
-20.3%
3/17 Seres Therapeutics (MCRB) Presents At Cowen and Comapny 40th Annual Health Care Conference - Slideshow [Seeking Alpha] -9.6%
6/28 Form 3 Seres Therapeutics, Inc. For: Jun 18 Filed by: Nutritional Health LTP Fund General Partner LLC -8.4%
11/5 Seres Therapeutics Inc (MCRB) Q3 2019 Earnings Call Transcript [The Motley Fool] -8.1%
11/27 Form 424B5 Seres Therapeutics, Inc. -8.1%
5/11 Seres Therapeutics Inc (NASDAQ: MCRB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.4%
3/31 Seres Therapeutics Inc (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock. -6.8%
10/22 Seres Therapeutics Inc (NASDAQ: MCRB) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -6.6%
8/6 Q2/2019 6/30/2019 EPS -0.240 ZacksConsensus -0.410 ActVsEst 0.170 - Beat -6.1%
2/14 Form SC 13G/A Seres Therapeutics, Inc. Filed by: ARK Investment Management LLC -5.9%
3/17 Seres Therapeutics (MCRB) Presents At Cowen and Comapny 40th Annual Health Care Conference - Slideshow [Seeking Alpha] -9.6%
6/28 Form 3 Seres Therapeutics, Inc. For: Jun 18 Filed by: Nutritional Health LTP Fund General Partner LLC -8.4%
11/5 Seres Therapeutics Inc (MCRB) Q3 2019 Earnings Call Transcript [The Motley Fool] -8.1%
11/27 Form 424B5 Seres Therapeutics, Inc. -8.1%
5/11 Seres Therapeutics Inc (NASDAQ: MCRB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.4%
3/31 Seres Therapeutics Inc (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock. -6.8%
10/22 Seres Therapeutics Inc (NASDAQ: MCRB) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -6.6%
8/6 Q2/2019 6/30/2019 EPS -0.240 ZacksConsensus -0.410 ActVsEst 0.170 - Beat -6.1%
2/14 Form SC 13G/A Seres Therapeutics, Inc. Filed by: ARK Investment Management LLC -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: